EP3723755A2 - Kombinationen mit einem skelettmuskelrelaxans und einem behandlungsmittel gegen multiple sklerose - Google Patents

Kombinationen mit einem skelettmuskelrelaxans und einem behandlungsmittel gegen multiple sklerose

Info

Publication number
EP3723755A2
EP3723755A2 EP18915063.4A EP18915063A EP3723755A2 EP 3723755 A2 EP3723755 A2 EP 3723755A2 EP 18915063 A EP18915063 A EP 18915063A EP 3723755 A2 EP3723755 A2 EP 3723755A2
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical combination
tablets
combination according
weight
tizanidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18915063.4A
Other languages
English (en)
French (fr)
Other versions
EP3723755A4 (de
Inventor
Ali TÜRKYILMAZ
Nur PEHLIVAN AKALIN
Arzu Palantöken
Sibel ZENGINER
Merve PEKER
Emine TUNCAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP3723755A2 publication Critical patent/EP3723755A2/de
Publication of EP3723755A4 publication Critical patent/EP3723755A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Definitions

  • the present invention relates to combinations which comprise at least one skeletal muscle relaxant agent and at least one multiple sclerosis treating agent.
  • MS Multiple Sclerosis
  • CNS central nervous system
  • spasticity a condition called spasticity. It happens mostly in the muscles of the legs and arms, and it may keep you from moving your limbs freely. Certain things can trigger them, and they can make the daily activities difficult.
  • fingolimod is 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1 ,3-diol.
  • Fingolimod is used in the treatment of the relapsing form of multiple sclerosis. May also be used in chronic inflammatory demyelinating polyneuropathy and shown as Formula I.
  • fingolimod derivatives first disclosed in US5604229.
  • the use of fingolimod derivatives as immunodepressant and a preventive or remedy for autoimmune diseases is disclosed in EP0627406 (B1 ).
  • the use of fingolimod derivatives in the prevention or treatment of chronic rejection in a recipient of organ or tissue alio- or xenotransplant is disclosed in EP0941082 (B1 ).
  • Skeletal muscle relaxant agents are often prescribed for musculoskeletal conditions including low back pain, neck pain, fibromyalgia, tension headaches, and myofascial pain syndrome.
  • the goals of treatment include managing muscle pain and improving functional status so the patient can return to work or resume previous activities.
  • Tizanidine, baclofen, diazepam, methocarbamol, dantrolene, carisoprodol, chlorzoxazone, cyclobenzaprine, metaxalone, orphenadrine are known as skeletal muscle relaxant agent.
  • tizanidine is 5-chloro-N-(4,5-dihydro-1 H-imidazol-2-yl)-2,1 ,3- benzothia-diazol-4-amine. It is a centrally acting skeletal muscle relaxant that acts mainly at spinal and supraspinal levels to inhibit excitatory interneurons and shown in Formula II.
  • baclofen 4-amino-3-(4-chlorophenyl) butanoic acid and is generally represented as follows in Formula III;
  • the main object of the present invention is to provide combinations of a skeletal muscle relaxant agent and multiple sclerosis treating agent, eliminating multiple sclerosis symptoms which is stiff muscles and spasms and bringing additional advantages over the relevant prior art.
  • Another object of the present invention is to obtain excellent content uniformity and a desired dissolution.
  • Another object of the present invention is to provide a pharmaceutical formulation that allows to obtain safe and efficient plasma levels of each pharmacological agents.
  • skeletal muscle relaxant agent refers to skeletal muscle relaxant agent in the form the free base or in the form of pharmaceutically acceptable salts, crystalline polymorph, solvates, hydrates, esters or mixture thereof.
  • Skeletal muscle relaxant agents are a diverse group of medicines that have the ability to relax or reduce tension in muscle. The agents work in the brain or spinal cord to block over-excited neuronal (nerve) pathways.
  • Some of skeletal muscle relaxant agents are tizanidine, baclofen, methocarbamol, dantrolene, carisoprodol, chlorzoxazone, cyclobenzaprine, metaxalone and orphenadrine.
  • multiple sclerosis treating agent refers to multiple sclerosis treating agent in the form the free base or in the form of pharmaceutically acceptable salts, crystalline polymorph, solvates, hydrates, esters or mixture thereof. Multiple sclerosis treating agents are used in multiple sclerosis to modify the disease course, treat relapses and manage symptoms. Some of multiple sclerosis treating agents are fingolimod, dimethyl fumarate, teriflunomide, dalfampridine, glatiramer.
  • combining more than one molecule in one dosage form increases the patient’s compliance.
  • this combination is increasing the patients’ quality of life, combining more than one molecule in one dosage form is also reduce undesired multiple sclerosis symptoms which can be stiff muscles and spasms.
  • molecules should be compatible with each other to achieve desired stability and dissolution for the patient’s compliance.
  • One embodiment of this invention is to provide a pharmaceutical combination comprises at least one skeletal muscle relaxant agent and at least one multiple sclerosis treating agent. Along with the other essential components of comprehensive MS care, these combinations help people to manage their MS and enhance their comfort and quality of life.
  • suitable multiple sclerosis treating agents are selected from the group comprising fingolimod, dimethyl fumarate, teriflunomide, dalfampridine, glatiramer or mixtures thereof.
  • suitable skeletal muscle relaxant agents are selected from group comprising tizanidine, baclofen, methocarbamol, dantrolene, carisoprodol, chlorzoxazone, cyclobenzaprine, metaxalone and orphenadrine or mixtures thereof.
  • skeletal muscle relaxant agent is tizanidine or baclofen.
  • the amount of tizanidine is between 0.3%-40.0% by weight of the total composition.
  • the amount of baclofen is between 0.3%-40.0% by weight of the total composition.
  • the amount of tizanidine or baclofen provides effective treatment.
  • the combination is selected from tizanidine with fingolimod, tizanidine with dimethyl fumarate, tizanidine with teriflunomide, tizanidine with dalfampridine, tizanidine with glatiramer.
  • the combination is selected from baclofen with fingolimod, baclofen with dimethyl fumarate, baclofen with teriflunomide, baclofen with dalfampridine, baclofen with glatiramer.
  • the combination comprises at least one pharmaceutically acceptable excipient which is selected from fillers, binders, disintegrants, diluents, dispersing agents, lubricants/glidants, surfactant, plasticizers, melting components, inert agent, stabilizers, rate controlling polymers, coating agents, coloring agents or mixtures thereof.
  • pharmaceutically acceptable excipient which is selected from fillers, binders, disintegrants, diluents, dispersing agents, lubricants/glidants, surfactant, plasticizers, melting components, inert agent, stabilizers, rate controlling polymers, coating agents, coloring agents or mixtures thereof.
  • Suitable fillers are selected from group comprising microcrystalline cellulose, calcium hydrogen phosphate dihydrate, ammonium alginate, calcium carbonate, dibasic calcium phosphate, calcium sulfate, cellulose, cellulose acetate, dextrates, dextrin, dextrose, erythritol, ethylcellulose, fructose, glyceryl palmitostearate, hydrogenated vegetable oil type I, isomalt, kaolin, lactitol, lactose, mannitol, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides, polydextrose, polymethacrylates, polyvinylpyrrolidone, simethicone, sodium alginate, sodium chloride, sorbitol, starch, sucrose, sugar spheres, sulfobutylether beta-cyclodextrin, talc, tragacanth, trehalose, polysorbate
  • the amount of fillers is between 20.0%- 85.0% by weight of the total composition. Preferably, it is between 30.0%-75.0% by weight of the total composition, more preferably it is between 35.0%-70.0% by weight of the total composition.
  • binders are used in this invention to achieve the desired dissolution of the combination.
  • Suitable binders are selected from the group comprising polyethylene glycols, dibasic calcium phosphate, polyvinylpyrrolidone (povidone), sugars, glucose syrup, natural gums, gelatin, collagen, gelatin, agar, alginates, carbomers, carboxymethylcellulose sodium, cellulose acetate phthalate, chitosan, copovidone, starch, corn starch , pregelatinized starch, starch mucilage, acacia mucilage, dextrates, dextrin, dextrose, ethylcellulose, glyceryl behenate, guar gum, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, hypromellose, liquid glucose, magnesium aluminum silicate, maltodextrin, maltose, methylcellulose, pectin,
  • the amount of binders is between 0.5%- 8.0% by weight of the total composition. Preferably, it is between 0.5%-7.0% by weight of the total composition, more preferably it is between 0.5%-6.0% by weight of the total composition.
  • Suitable disintegrants are selected from the group comprising cross-linked polyvinil pyrrolidone (crospovidone), povidone, cross-linked carboxymethyl cellulose (croscarmellose sodium), low-substituted hydroxypropyl cellulose, pregelatinized starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, polyacrylate potassium, sodium alginate, corn starch, sodium starch glycolate, alginic acid, alginates, ion-exchange resins, magnesium aluminium silica, sulphate, poloxamer, sodium glycine carbonate, sodium lauryl sulphate or mixtures thereof.
  • cross-linked polyvinil pyrrolidone crospovidone
  • povidone cross-linked carboxymethyl cellulose
  • croscarmellose sodium cross-linked carboxymethyl cellulose
  • low-substituted hydroxypropyl cellulose pregelatinized starch
  • Suitable diluents are selected from the group comprising microcrystalline cellulose, mannitol, spray-dried mannitol, lactose, lactose monohydrate, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
  • Suitable dispersing agents are selected from the group comprising calcium silicate, magnesium aluminum silicate, sorbitan esters, aluminum oxide, phospholipids, poloxamer or mixtures thereof.
  • Suitable lubricants/glidants are selected from the group comprising sodium stearyl fumarate, magnesium stearate, colloidal silicon dioxide, calcium stearate, zinc stearate, talc, waxes, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, polyethylene glycol, stearic acid, fatty acid, fumaric acid, glyceryl palmito sulphate, sodium lauryl sulphate, aluminium silicate, colloidal silica, calcium silicate, magnesium silicate, magnesium oxide, starch or mixtures thereof.
  • Suitable surfactants are selected from the group comprising sodium lauryl sulfate, cetylpyridinium chloride, docusate sodium, lauric acid, polyoxyethylene sorbitan fatty acid esters (polysorbate), phospholipids, cetrimide or mixtures thereof.
  • Suitable plasticizers are selected from the group comprising polyethylene glycols of different molecular weights, triacetin, tributyl citrate, triethyl citrate, chlorobutanol, dibutyl phthalate, dibutyl sebacate, dimethyl phthalate, glycerin, mannitol, petrolatum and lanolin alcohols, propylene glycol or mixtures thereof.
  • Suitable melting components are selected from the group comprising gelucire (stearyl macrogolglyceride), poloxamer (polyoxyethylene-polyoxypropylene block copolymer), polyethylene glycol, povidone, soluplus, cationic methacrylate, copovidone, methacrylic acid copolymers, cellulose acetate phthalate, acetylated monoglyceride, butyl phthalyl butyl glycolate, dibutyl tartrate, diethyl phthalate, dimethyl phthalate, ethyl phthalylethly glycolate, glycerin, propylene glycol, triacetin, triacetin citrate, tripropionin or mixtures thereof.
  • gelucire stearyl macrogolglyceride
  • poloxamer polyoxyethylene-polyoxypropylene block copolymer
  • polyethylene glycol povidone
  • povidone soluplus
  • cationic methacrylate copovidone
  • Suitable inert agents between the two molecules wherein the inert agent is selected from starch, lactose, D-mannitol, erythritol; lowsubstituted hydroxypropyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, methylcellulose, hydroxyethyl methylcellulose or mixtures thereof.
  • Suitable stabilizers are selected from the group comprising sucrose, citric acid, fumaric acid, tartaric acid, sodium citrate, sodium benzoate, sodium dihydrogen phosphate, calcium carbonate, magnesium carbonate, arginine, lysine, meglamine, ascorbic acid, gallic acid esters or the mixtures thereof, and preferably citric acid, fumaric acid, arginine or mixtures thereof.
  • Suitable rate controlling polymers are selected from the group comprising ethyl acrylate, polymethacrylates ( Eudragit ), ethyl methacrylate copolymer, ethylcellulose, methylcellulose, hypromellose phthalate, polydextrose, polyvinylacetate phthalate, zein, polyvinylpyrrolidone,, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl cellulose, hydroxypropyl methylcellulose (HPMC), hydroxyethyl cellulose, hydroxymethyl cellulose, gelatin, polyethylene oxide, acacia, dextrin, starch, polyhydroxyethylmethacrylate, sodium carboxymethylcellulose, sodium alginate, alginic acid, pectin, polyglucoronic acid, polygalacturonic acid, chondroitic sulfate, carrageenan, lambda carregeenan, iota carregeenan, furcellaran, xant
  • Suitable coating agents are selected from the group comprising hydroxypropyl methylcellulose, lactose monohydrate, hydroxypropyl cellulose, polyvinyl alcohol (PVA), polyethylene glycol (PEG), talc, polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat® IR), ethylcellulose dispersions (Surelease®), polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA), all kinds of Opadry®, pigments, dyes, titanium dioxide, iron oxide or mixtures thereof.
  • Suitable coloring agents are selected from the group comprising ferric oxide, titanium dioxide, Food, Drug & Cosmetic (FD&C) dyes (such as; FD&C blue, FD&C green, FD&C red, FD&C yellow, FD&C lakes), poncau, indigo Drug & Cosmetic (D&C) blue, indigotine FD&C blue, carmoisine indigotine (indigo Carmine); iron oxides (such as; iron oxide red, yellow, black), quinoline yellow, flaming red, carmine, carmoisine, sunset yellow or mixtures thereof.
  • FD&C Food, Drug & Cosmetic
  • the pharmaceutical combination is administered orally.
  • the pharmaceutical combination is in the form of capsules, tablets, strips, syrups, powders, pastilles, sachet, effervescent compositions, pills, hard or soft gelatin capsules, coated bead systems, granules, microspheres, dragees, films, orally administrable films, solutions, solids, elixirs, tinctures, suspensions, colloidal dispersions, dispersions or emulsions.
  • the pharmaceutical combination is in the form of capsules or tablets or pastilles or strips. According to one embodiment of the present invention, the pharmaceutical combination is in the form of capsule.
  • the pharmaceutical combination is in the form of tablet.
  • the pharmaceutical combination is formulated as tablets comprising compressed tablets, coated or uncoated tablets, multilayer tablets, mini tablets, bilayer tablet, pellet in tablet, buccal tablets, sublingual tablets, effervescent tablets, immediate release tablets, core-in-tablet, modified release tablets, tablet-in-tablet, film-coated tablets, orally disintegrating tablets, gastric disintegrating tablets, chewable tablet, dispersing tablet, lozenges.
  • the pharmaceutical combination may comprise a film coating as necessary.
  • said tablets or capsules comprises at least one type of particle. Furthermore, each particle comprises at least one active agent.
  • At least one type of particle is mini capsule, mini-tablet, pellets, agglomerates, granules, powder, liposomes, sphericals or mixtures thereof.
  • An embodiment of this present invention is to combine skeletal muscle relaxant agent and multiple sclerosis treating agent in a same and stable dosage form with desired dissolution profiles.
  • compositions of invention may be developed as immediate release formulation, extended release formulation, sustained release formulation, controlled release formulation, modified release formulation, delayed release formulation or thereof combination.
  • composition comprising at least one of the following drug combinations for combined, separate or sequential administration: -tizanidine, fingolimod or their pharmaceutically acceptable salt, solvate or polymorph -tizanidine, dimethyl fumarate or their pharmaceutically acceptable salt, solvate or polymorph
  • the pharmaceutical combination of the present invention can be prepared, using standard techniques and manufacturing processes well known in the art, such as direct compression, wet or dry granulation, hot melt granulation, hot melt extrusion, fluidized bed granulation, extrusion, spheronization, slugging, spray drying or solvent evaporation.
  • Example 1 Capsule comprising skeletal muscle relaxant agent and multiple sclerosis treating agent
  • the process for preparation of the combination comprises the following steps:
  • Example 2 Capsule comprising fingolimod and tizanidine
  • Example 3 Capsule comprising fingolimod and tizanidine
  • the process for preparation of the combination comprises the following steps:
  • Example 5 Capsule comprising fingolimod and baclofen
  • the process for preparation of the pharmaceutical combination comprises the following steps:
  • Example 6 Film-coated tablet comprising fingolimod and tizanidine
  • the pharmaceutical combinations mentioned above are prepared by following these steps: a. Mixing fingolimod, tizanidine, or pharmaceutically acceptable polymorphs thereof, microcrystalline cellulose, dibasic calcium phosphate, polyethylene glycol and pregelatinized starch.
  • Example 7 Film-coated tablet comprising fingolimod and baclofen
  • the pharmaceutical combinations mentioned above are prepared by following these steps: a. Mixing fingolimod, baclofen, or pharmaceutically acceptable polymorphs thereof, microcrystalline cellulose, dibasic calcium phosphate, polyethylene glycol and pregelatinized starch.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP18915063.4A 2017-12-14 2018-12-12 Kombinationen mit einem skelettmuskelrelaxans und einem behandlungsmittel gegen multiple sklerose Withdrawn EP3723755A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/20406A TR201720406A2 (tr) 2017-12-14 2017-12-14 Bi̇r i̇skelet kasi gevşeti̇ci̇si̇ ve bi̇r multi̇pl skleroz tedavi̇ edi̇ci̇ ajan i̇çeren kombi̇nasyonlar
PCT/TR2018/050800 WO2019203752A2 (en) 2017-12-14 2018-12-12 Combinations comprising a skeletal muscle relaxant agent and a multiple sclerosis treating agent

Publications (2)

Publication Number Publication Date
EP3723755A2 true EP3723755A2 (de) 2020-10-21
EP3723755A4 EP3723755A4 (de) 2021-09-15

Family

ID=67900478

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18915063.4A Withdrawn EP3723755A4 (de) 2017-12-14 2018-12-12 Kombinationen mit einem skelettmuskelrelaxans und einem behandlungsmittel gegen multiple sklerose

Country Status (3)

Country Link
EP (1) EP3723755A4 (de)
TR (1) TR201720406A2 (de)
WO (1) WO2019203752A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201818859A2 (tr) * 2018-12-07 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇meti̇l fumarat ve en az bi̇r kas gevşeti̇ci̇ ajan i̇çeren bi̇r kombi̇nasyon
TR201819202A2 (tr) * 2018-12-12 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Bi̇r multi̇pl skleroz ajani ve en az bi̇r kas relaksan ajan i̇çeren bi̇r kombi̇nasyon
TR201820976A2 (tr) * 2018-12-28 2020-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fi̇ngoli̇mod ve bi̇r spazmoli̇ti̇k i̇çeren farmasöti̇k kombi̇nasyonlar
JP7503420B2 (ja) 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2966195C (en) 2014-11-04 2024-04-30 Adamas Pharmaceuticals, Inc. Oral adamantine in the treatment of gait disorders in multiple sclerosis patients
WO2017031276A1 (en) * 2015-08-19 2017-02-23 The Regents Of The University Of California Methods of providing neuroprotective therapy related to administering an estrogen receptor beta ligand

Also Published As

Publication number Publication date
EP3723755A4 (de) 2021-09-15
WO2019203752A3 (en) 2020-01-16
WO2019203752A2 (en) 2019-10-24
TR201720406A2 (tr) 2019-07-22

Similar Documents

Publication Publication Date Title
WO2019203752A2 (en) Combinations comprising a skeletal muscle relaxant agent and a multiple sclerosis treating agent
WO2008064202A2 (en) Modified-release formulations of calcium receptor-active compounds
CN109310642B (zh) 美沙拉嗪的口服药物组合物
US20100136119A1 (en) Controlled-release preparation containing cilostazol and process for the preparation thereof
US20070134315A1 (en) Orally administrable extended release pellet and tablet formulations of a highly water soluble compound
WO2017208136A1 (en) Pharmaceutical composition of dapagliflozin co-crystal
JP7021108B2 (ja) ニコチンアミドの経口薬学的組成物
WO2007112574A1 (en) Extended release composition of venlafaxine
US11576917B2 (en) Pharmaceutical compositions comprising Ibrutinib
JP2023181218A (ja) 持続放出ミドドリン塩酸塩組成物及び使用方法
US9561242B2 (en) Doxycycline composition
CA2919720A1 (en) Pharmaceutical compositions of ranolazine and dronedarone
EP2503996A2 (de) Pharmazeutische retard-zusammensetzungen aus galantamin
US20160143923A1 (en) Low dose pharmaceutical composition of doxycycline
US9566287B2 (en) Pharmaceutical composition of doxycycline with reduced food effect
EP3727365A2 (de) Modifizierte freisetzungsformulierungen von flurbiprofen
JP7352175B2 (ja) トルバプタン製剤
EP3810112A2 (de) Kombination aus fingolimod und modafinil
EP3810110A2 (de) Kombination aus fingolimod und amantadin
WO2024084496A1 (en) Pharmaceutical compositions comprising acalabrutinib maleate
CN108472260B (zh) 用于制备包括富马酸二甲酯的肠溶包衣颗粒的方法
EP3886835A2 (de) Kapsel mit verzögerter freisetzung mit dimethylfumarat
US20160143924A1 (en) Low dose pharmaceutical composition of doxycycline
WO2019203748A2 (en) The composition comprising raloxifene with at least one antipsychotic agent
EP3810274A2 (de) Kombination aus fingolimod und mindestens einem antiepileptikum

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200710

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210816

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/00 20060101ALI20210810BHEP

Ipc: A61P 21/02 20060101ALI20210810BHEP

Ipc: A61K 9/48 20060101ALI20210810BHEP

Ipc: A61K 9/20 20060101ALI20210810BHEP

Ipc: A61K 31/137 20060101ALI20210810BHEP

Ipc: A61K 31/195 20060101ALI20210810BHEP

Ipc: A61K 31/433 20060101AFI20210810BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20221118

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230531